Aprea Therapeutics Inc./$APRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Ticker
$APRE
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
8
ISIN
US03836J2015
Website
APRE Metrics
BasicAdvanced
$9.1M
-
-$2.37
-
-
Price and volume
Market cap
$9.1M
52-week high
$2.79
52-week low
$1.41
Average daily volume
24K
Financial strength
Current ratio
5.901
Quick ratio
5.735
Management effectiveness
Return on assets (TTM)
-35.70%
Return on equity (TTM)
-59.80%
Valuation
Price to revenue (TTM)
7.701
Price to book
0.59
Price to tangible book (TTM)
0.59
Price to free cash flow (TTM)
-0.746
Growth
Revenue change (TTM)
33.27%
Earnings per share change (TTM)
-28.33%
3-year earnings per share growth (CAGR)
-58.33%
APRE News
AllArticlesVideos
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
GlobeNewsWire·1 week ago
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial
GlobeNewsWire·2 months ago
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aprea Therapeutics Inc. stock?
Aprea Therapeutics Inc. (APRE) has a market cap of $9.1M as of May 23, 2025.
What is the P/E ratio for Aprea Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Aprea Therapeutics Inc. (APRE) stock is 0 as of May 23, 2025.
Does Aprea Therapeutics Inc. stock pay dividends?
No, Aprea Therapeutics Inc. (APRE) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Aprea Therapeutics Inc. dividend payment date?
Aprea Therapeutics Inc. (APRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aprea Therapeutics Inc.?
Aprea Therapeutics Inc. (APRE) does not currently have a Beta indicator.